Contravir Pharmaceut (CTRV) 2.1100 $CTRV
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 36.80 (+0.70), GILD: 91.29 (+1.84)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 3.08 (+0.12), CMRX: 36.80 (+0.70)
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
PR Newswire - Tue Dec 16, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the formation of a Scientific Advisory Board (SAB) to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D., global expert in post herpetic neuralgia (PHN) pain management and President and Chief Executive Officer of Analgesic Solutions, a research, education, and consulting firm focused exclusively on pain therapeutics, has joined ContraVir as Chairman of the newly formed SAB.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals' CEO Issues Letter to Shareholders Highlighting Significant Progress
PR Newswire - Thu Dec 11, 9:10AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its Chief Executive Officer James Sapirstein issued a letter to shareholders highlighting the significant progress the company has made toward its vision of becoming a leading developer of targeted antiviral therapies.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Tue Dec 09, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Wed Nov 05, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place November 10-13, 2014 at Oxford University in the UK. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Thu Oct 16, 5:58AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading contract research organization (CRO), to conduct a Phase 2b clinical trial of ContraVir's lead clinical asset, FV-100, in shingles patients. The planned Phase 2b study is designed to measure the efficacy of FV-100 for treating the severe, lingering nerve pain commonly associated with shingles known as post-herpetic neuralgia (PHN), as well as to optimize the dose and regimen to be used for registration studies.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals raises USD9.0m in private placement of Series A convertible preferred stock
M2 - Thu Oct 16, 5:08AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (OTC BB :CTRV) revealed on Wednesday the completion of USD9.0m in private placement of Series A convertible preferred stock with a non US investor .
ContraVir Pharma raises capital to fund development of shingles product candidate
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 3:26PM CDT
ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
PR Newswire - Wed Oct 15, 5:58AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has closed a private placement of shares of Series A Convertible Preferred Stock to a non-U.S. investor with gross proceeds of $9.0 million. The Preferred Stock is convertible at any time into shares of common stock at a conversion price of $0.48 per share. The investor has agreed to lock-up the shares of Preferred Stock and the underlying common stock until April 14, 2016.
SGYP: 3.08 (+0.12)
Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors.
BMY: 59.15 (-0.01), TBRA: ()
ContraVir to Present at Two Upcoming Investor Conferences
PR Newswire - Wed Sep 03, 3:42PM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, to be held September 8-10, 2014, in New York City, and the Aegis Capital 2014 Healthcare and Technology Conference, to be held September 10-13, 2014 in Las Vegas.
SGYP: 3.08 (+0.12)
ContraVir Appoints Industry Veteran William Hornung as Its Chief Financial Officer
Business Wire - Tue Jul 08, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that William Hornung has joined the Company as its Chief Financial Officer. Mr. Hornung has over 22 years of finance and operations leadership experience in the biopharmaceutical industry with companies such as PTC Therapeutics (NASDAQ
TCT), Elan Pharmaceuticals, and The Liposome Company.
SGYP: 3.08 (+0.12), PTCT: 51.66 (+0.76)
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 36.80 (+0.70), GILD: 91.29 (+1.84)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 3.08 (+0.12), CMRX: 36.80 (+0.70)
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
PR Newswire - Tue Dec 16, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the formation of a Scientific Advisory Board (SAB) to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D., global expert in post herpetic neuralgia (PHN) pain management and President and Chief Executive Officer of Analgesic Solutions, a research, education, and consulting firm focused exclusively on pain therapeutics, has joined ContraVir as Chairman of the newly formed SAB.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals' CEO Issues Letter to Shareholders Highlighting Significant Progress
PR Newswire - Thu Dec 11, 9:10AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its Chief Executive Officer James Sapirstein issued a letter to shareholders highlighting the significant progress the company has made toward its vision of becoming a leading developer of targeted antiviral therapies.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Tue Dec 09, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Wed Nov 05, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place November 10-13, 2014 at Oxford University in the UK. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Thu Oct 16, 5:58AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading contract research organization (CRO), to conduct a Phase 2b clinical trial of ContraVir's lead clinical asset, FV-100, in shingles patients. The planned Phase 2b study is designed to measure the efficacy of FV-100 for treating the severe, lingering nerve pain commonly associated with shingles known as post-herpetic neuralgia (PHN), as well as to optimize the dose and regimen to be used for registration studies.
SGYP: 3.08 (+0.12)
ContraVir Pharmaceuticals raises USD9.0m in private placement of Series A convertible preferred stock
M2 - Thu Oct 16, 5:08AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (OTC BB :CTRV) revealed on Wednesday the completion of USD9.0m in private placement of Series A convertible preferred stock with a non US investor .
ContraVir Pharma raises capital to fund development of shingles product candidate
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 3:26PM CDT
ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
PR Newswire - Wed Oct 15, 5:58AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has closed a private placement of shares of Series A Convertible Preferred Stock to a non-U.S. investor with gross proceeds of $9.0 million. The Preferred Stock is convertible at any time into shares of common stock at a conversion price of $0.48 per share. The investor has agreed to lock-up the shares of Preferred Stock and the underlying common stock until April 14, 2016.
SGYP: 3.08 (+0.12)
Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors. BMY: 59.15 (-0.01), TBRA: ()
ContraVir to Present at Two Upcoming Investor Conferences
PR Newswire - Wed Sep 03, 3:42PM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, to be held September 8-10, 2014, in New York City, and the Aegis Capital 2014 Healthcare and Technology Conference, to be held September 10-13, 2014 in Las Vegas.
SGYP: 3.08 (+0.12)
ContraVir Appoints Industry Veteran William Hornung as Its Chief Financial Officer
Business Wire - Tue Jul 08, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that William Hornung has joined the Company as its Chief Financial Officer. Mr. Hornung has over 22 years of finance and operations leadership experience in the biopharmaceutical industry with companies such as PTC Therapeutics (NASDAQ
TCT), Elan Pharmaceuticals, and The Liposome Company. SGYP: 3.08 (+0.12), PTCT: 51.66 (+0.76)
